Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT, or definitive chemotherapy or chemotherapy-immunotherapy and will be considered separately as a single arm prospective cohort

NCT Number	NCT04682158
Lead Sponsor	Roswell Park Cancer Institute
Conditions	Esophageal Adenocarcinoma
Enrollment	106 participants
Start Date	2021-04-01
Primary Completion	2029-04-01 (estimated)
Study Completion	2029-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-02